The biographies of each of our senior managers and directors are as follows:

	Marc C. Whyte, Director, President and Chief Executive Officer, co-founded NovaRay in June 2005. Mr. Whyte has extensive financing and operational experience in high-technology and industrial enterprises, has over 25 years experience as an executive manager, and has served as a director on a number of boards. Mr. Whyte has been chairman of Triple Ring Technologies since February 2005. From 1992 to June 2005, Mr. Whyte held the positions of CFO, President, and CEO of NexRay Inc., formally known as Cardiac Mariners Inc. During that period, he raised over $80 million in venture capital funding for the company. Previously, Mr. Whyte was President and CEO of Engine Parts Corporation, a privately held company specializing in the re-manufacturing of automotive engines. Mr. Whyte grew Engine Parts Corp. to manufacturing and selling over 6,000 engines annually. In 1989, Mr. Whyte negotiated a successful acquisition of the company and remained President until 1992. From 1971 to 1984, he was President and CEO of Goodies Auto Stores, Inc. where he developed and built a chain of automotive parts stores located in Northern California.
	Edward G. Solomon, Director, Chief Technical Officer, co-founded NovaRay in June 2005. Mr. Solomon has over 25 years experience in the development and commercialization of technology in venture-financed companies in Silicon Valley. Mr. Solomon has been a co-founder and director of Triple Ring Technologies since February 2005. Mr. Solomon worked at NexRay from 1993 to December 2004 and was responsible for developing the architecture and much of the intellectual property in the cardiac catheterization system, now owned by NovaRay. He is a named inventor on 12 of NovaRay’s patents. Previously Mr. Solomon was Vice President of Engineering at Resumix, Inc. From 1986 to 1992, he was a General Partner of Dillon Read Venture Capital responsible for technology investments and a director on four portfolio company boards. From 1979 to 1985, he was a Senior Engineer and Project Manager at Oximetrix, Inc., a manufacturer of patient-monitoring equipment and drug-delivery systems. Mr. Solomon holds B.S. and M.S. degrees in Electrical Engineering from the University of Cape Town and an M.S. from the Stanford Graduate School of Business.
	Russell M. Singleton, Ph.D., Chief Operating Officer, joined NovaRay in January, 2012. Dr. Singleton has over 30 years of transformational achievements in general management, marketing, strategic business development and engineering in medical and semiconductor capital equipment businesses. From 2008 to 2011, Dr. Singleton was President and CEO of Molecular Image, an early stage medical diagnostics company, where he continues as director. From 2006 to 2007, he was General Manager of the Single Positron Emission CT Business at Philips Healthcare, where he drove a successful turnaround which resulted in almost doubling in market share and significant improvement in profitability. Prior to Philips, Dr. Singleton was Vice President of Engineering and Informatics at Perlegen Sciences, a venture-backed personalized medicine company. From 1995 to 2003, Dr. Singleton was Vice President and General Manager at KLA-Tencor, a semiconductor inspection and metrology company leading businesses spanning instrumentation, software and consulting. Before KLA-Tencor, Dr. Singleton was Vice President of Engineering at Molecular Dynamics, a life sciences tools company. Prior to Molecular Dynamics, Dr. Singleton was at KLA Instruments starting from Sr. Scientist advancing through Vice President of the Metrology Business Unit. Dr. Singleton received his B.E. (Electrical) from Pratt Institute, and his M.S. and Ph.D. from the University of Illinois in Electrical Engineering. He completed the AEA/Stanford University Executive Institute program on Management of High Tech Companies while at KLA-Tencor.
	Lynda L. Wijcik, Chairman, is Managing Partner of BioBridge LLC. From January 1995 to September 2006 Ms. Wijcik consulted, invested and assisted companies in financings as a managing partner of her consulting firm Biobridge Associates. In October 2006 Biobridge LLC was formed by Ms. Wijcik and her husband to do Investments. Ms. Wijcik has a background in cancer and genetic disease research at the University of British Columbia, the Hospital for Sick Children in Toronto, Canada, and the Memorial Sloan Kettering Cancer Center in New York. Over the past few years, she has assisted in growing two biotech companies, Metra Biosystems (acquired by Quidel) and Connetics (acquired by Steifel Laboratories). At both these companies, she was part of the founding team, helping them to obtain venture capital funding, and was Vice President of Marketing and Vice President of Business Development, respectively. She has assisted several biotech companies in raising over $100 million in seed, first, and second round venture capital financing. These companies include NexRay, Geron, Connetics, Metra Biosystems, Nanogen, Onyx Pharmaceuticals, and Origen Therapeutics. She is a Director of Origen Therapeutics, NovaRay, Medispectra, and United Systems Access, a telecommunications company. She received her B.S.C. degree from Simon Fraser University (Canada).
	George J.M. Hersbach, Director, is the founder and Chairman and CEO of Heartstream Group since July 2002, an investment corporation which specializes in the financing of innovative companies (healthcare, cleantech, and technology). Mr. Hersbach formed partnerships with major healthcare companies and raised more than € 500 million in various forms of financing. Mr. Hersbach is a director on several boards, including Theolia (France) Global Interface (France), EU’s Enterprise Policy for SME’s (of European Commission, Belgium), and he is an advisor to the board of several companies. Prior to his current position, from February 1993 to July 2002, he was President & CEO of Pharming Group, a publicly traded biopharmaceutical company. From May 1987 to February 1993, Mr. Hersbach was founder and Vice President of Operations at EuroCetus (part of Cetus, later Chiron, now Novartis), and from February 1977 to May 1987, he held international research and development and manufacturing management positions at Gist-brocades (now DSM). Mr. Hersbach is an entrepreneur with thirty years of industrial experience with private and publicly traded companies in various EU countries and several US states and he holds a Master of Science (cum laude) in Chemical Technology from the University of Technology of Delft, Netherlands (January 1977), and a European Engineering diploma from FEANI in Paris, France (September 1990).
	David J. Foster, Director, is the Executive Vice President and Chief Financial Officer of diaDexus, Inc., a private medical technology company, since February 2007. From July 2005 to January 2007, Mr. Foster was a consultant for various life sciences companies. From April 2002 to June 2005, he was the Senior Vice President and Chief Financial Officer of Argonaut Technologies, Inc., a public life sciences instrument company. From December 1997 to October 2001, he was the Chief Executive Officer of Cohesion Technologies, Inc., a public medical technology company. Prior to that position, he held several positions at Collagen Corporation including General Manager, Senior Vice President, Chief Financial Officer and Vice President, Finance and Administration. He has served on the board of directors of numerous public and private companies including Cohesion Technologies, Inc., Innovasive Devices, Inc. and Pharming, N.V. Mr. Foster holds a B.S. in Mechanical Engineering and an M.B.A. from the University of California, Berkeley.